Peter Alping

About me
Publications
CV
Public outreach and news

About me

I'm a Postdoctoral Researcher at the Division of Clinical Epidemiology, Department of Medicine, Solna. My research is mainly focused on multiple sclerosis.

Articles

Article: ANNALS OF NEUROLOGY. 2024;95(6):1099-1111

Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study

Alping P; Neovius M; Piehl F; Frisell T
Article: MULTIPLE SCLEROSIS JOURNAL. 2023;29(6):731-740

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study

Fink K; Gorczyca A; Alping P; Englund S; Farmand S; Langer-Gould AM; Piehl F; McKay K; Frisell T; Razaz N
Article: NEUROLOGY. 2021;96(11):e1574-e1584

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

Alping P; Burman J; Lycke J; Frisell T; Piehl F
Article: ANNALS OF NEUROLOGY. 2020;87(5):688-699

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: JAMA NEUROLOGY. 2020;77(2):184-191

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Luna G; Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: EPIDEMIOLOGY. 2019;30(2):230-233

Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations

Alping P; Piehl F; Langer-Gould A; Frisell T; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Kockum I; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Virtanen S; Vrethem M
Article: NEUROLOGY. 2016;87(20):2074-2081

Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy

Salzer J; Svenningsson R; Alping P; Novakova L; Bjorck A; Fink K; Islam-Jakobsson P; Malmestrm C; Axelsson M; Vagberg M; Sundstrom P; Lycke J; Piehl F; Svenningsson A
Article: ANNALS OF NEUROLOGY. 2016;79(6):950-958

Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients

Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Lycke J; Svenningsson A; Piehl F

All other publications

Review: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2023;133(5):550-564

Disease-modifying therapies in multiple sclerosis: A focused review of rituximab

Alping P
Thesis / dissertation: 2022

Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis

Alping, Peter
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):106

Multiple sclerosis and risks for adverse perinatal and pregnancy outcomes: Results from a nationwide cohort study

Fink K; Gorczyca A; Alping P; Langer-Gould AM; Cnattingius S; Frisell T; Piehl F; Razaz N
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):634-635

Rituximab treatment prior to pregnancy in women with multiple sclerosis - perinatal outcomes in Swedish cohort

Gorczyca A; Alping P; Frisell T; Razaz N; Piehl F; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):21-22

Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab

Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Vrethem M; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):352-353

Safety outcomes after treatment with alemtuzumab or autologous hematopoietic stem cell transplantation in multiple sclerosis patients

Alping P; Burman J; Lycke J; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:570-571

Rituximab does not increase the risk of malignancy or breast cancer in two large US and Swedish rituximab-treated multiple sclerosis cohorts

Langer-Gould A; Alping P; Smith J; Li B; Piehl F; Frisell T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:36

Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab.

Alping P; Piehl F; Frisell T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:146-147

Disease-modifying therapies for multiple sclerosis in association with pregnancy: a Swedish nation-wide cohort study

Gorczyca A; Alping P; Frisell T; Piehl F; Langer-Gould A; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:714

Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location

Alping P; Burman J; Fink K; Gunnarsson M; Lycke J; Nilsson P; Salzer J; Vrethem M; Langer-Gould A; Svenningsson A; Frisell T; Piehl F
Letter: ANNALS OF NEUROLOGY. 2016;80(5):791-792

Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk Reply

Alping P; Frisell T; Svenningsson A; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:49

Rituximab in multiple sclerosis; data from the swedish MS registry.

Alping P; Svenningsson A; Salzer J; Burman J; Dahle C; Fink K; Hillert J; Lycke J; Landtblom A-M; Martin C; Nilsson P; Walentin F; Olsson T; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:574

Rituximab in multiple sclerosis, a long term safety and efficacy study

Islam-Jakobsson P; Alping P; Salzer J; Bjorck A; Fink K; Frisell T; Piehl F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:555

Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology

Alping P; Islam-Jakobsson P; Novakova L; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Frisell T; Lycke J; Svenningsson A; Piehl F

Employments

Postdoctoral Researcher, Department of Medicine, Karolinska Institutet, 2023-2025
Physician (AT-Läkare), Karolinska University Hospital, 2021-2023
Phd Student, Department of Clinical Neuroscience, Karolinska Institutet, 2016-2022
Physician, Stockholm Health Care Services (SLSO), 2020-2020

Degrees and Education

Doctor Of Philosophy, Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis, Department of Clinical Neuroscience, Karolinska Institutet, 2022
Degree Of Master Of Science In Medicine, Karolinska Institutet, 2017

About me

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI